Selank and antidepressants: interactions, risks, and evidence

Last updated 2026-07-30

What is selank, and how is it related to antidepressants?

Selank is a synthetic peptide developed in Russia, built from a fragment of tuftsin, an endogenous immunomodulatory peptide. Researchers at the Institute of Molecular Genetics (Russian Academy of Sciences) and the V.V. Zakusov Institute of Pharmacology designed it in the 1990s and 2000s as an anxiolytic without the sedation or dependence issues tied to benzodiazepines ^[1]. It is not an antidepressant in the classic sense. It doesn't work like an SSRI (blocking serotonin reuptake) or an SNRI (blocking serotonin and norepinephrine reuptake). Russian pharmacology papers describe it as affecting brain-derived neurotrophic factor (BDNF) expression and the balance of monoamines, with anxiolytic and mild nootropic effects reported in animal and small human studies ^[2]. Some of that research measured selank against or alongside tricyclic antidepressants, mainly amitriptyline, which is why the two keep getting mentioned together. If you're trying to figure out whether selank could replace or supplement an antidepressant prescription, the honest answer is that nobody has run the kind of large randomized controlled trial that would let you make that call with confidence. What exists is a stack of Russian-language studies, most from the 2000s and 2010s, several with fairly small sample sizes and outcome measures that Western journals rarely see replicated. For a wider look at how that evidence holds up, see selank reviews.

Is there published research on selank combined with antidepressants?

Yes, some. Selank has been studied as an add-on treatment for generalized anxiety disorder, including cases where patients were already on other psychiatric medication. A frequently cited Russian trial evaluated selank in patients with generalized anxiety disorder and adjustment disorders, reporting reduced anxiety scores over a two to four week course, with a safety profile described as favorable and without the withdrawal effects seen with benzodiazepines ^[3]. A separate line of research compared selank's effects to the tricyclic antidepressant amitriptyline in animal models of depression-like behavior, finding some overlapping antidepressant-like activity attributed to changes in monoamine and BDNF signaling ^[2]. That's a mechanistic and behavioral comparison, not a clinical trial of the two given together to depressed patients. What's missing entirely is any published randomized controlled trial testing selank as an adjunct specifically to SSRIs (fluoxetine, sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), or newer antidepressants like bupropion or mirtazapine. If a clinic or supplier tells you there's clinical evidence for stacking selank with your Lexapro or Zoloft, that claim outruns what's actually published. The gap is more than in translation, it's in the trial design itself. Nobody has run it.

Does selank interact with SSRIs or SNRIs?

There's no documented pharmacokinetic interaction between selank and SSRIs or SNRIs, but that absence reflects a lack of study, not a clean bill of health. Selank is a peptide, degraded by peptidases in blood and tissue rather than metabolized through the cytochrome P450 liver enzymes that SSRIs commonly use (CYP2D6, CYP2C19, CYP3A4). That's a mechanistic reason to expect lower interaction risk on paper, but mechanism-based reasoning is not the same as a documented drug interaction study. Both selank and serotonergic antidepressants touch serotonin signaling, even if through different routes. Serotonin syndrome, the dangerous overstimulation of serotonin receptors, is a real risk when combining multiple serotonergic agents (SSRIs plus MAOIs, SSRIs plus triptans, SSRIs plus tramadol, for example) ^[4]. Selank has not been implicated in any published serotonin syndrome case report, but that's likely because so few people have combined it with prescription antidepressants under any kind of medical observation, not because it's been cleared. The practical takeaway: if you're on an SSRI or SNRI and considering selank, you're in genuinely uncharted territory from a drug-interaction standpoint. That doesn't mean disaster is likely. It means nobody is tracking it, so if something goes wrong, there's no established pattern to recognize it against.

Can selank replace an antidepressant?

No, and no credible source is claiming it should. Selank's own Russian labeling and pharmacology literature position it as an anxiolytic (anti-anxiety agent) with some nootropic and mild antidepressant-adjacent effects, not as a first-line depression treatment ^[1][2]. It was approved for medical use in Russia for anxiety and related conditions through that country's regulatory process, which is a different bar than FDA approval in the United States. Selank is not FDA approved for any indication ^[5], and there is no equivalent New Drug Application or clinical trial pathway completed in the US or EU. Major depressive disorder has a real evidence base behind SSRIs, SNRIs, and other approved antidepressants: multi-thousand patient trials, decades of pharmacovigilance data, established dosing. Selank has none of that depth. Stopping a prescribed antidepressant to try selank instead, without a prescriber's involvement, risks a relapse of the underlying condition and, depending on the drug, a discontinuation syndrome (dizziness, irritability, flu-like symptoms) that has nothing to do with selank at all ^[6]. Where selank's research base is stronger is generalized anxiety and adjustment disorders with anxious features, conditions that sometimes overlap with but are distinct from major depression. See is selank worth it for a broader verdict on the cost-benefit picture.

Why do people confuse selank with semax?

Selank and semax are sibling peptides from the same Russian research lineage (the Institute of Molecular Genetics and the Zakusov Institute of Pharmacology), and they get lumped together constantly, but they're built differently and aimed at different things. Semax is derived from a fragment of ACTH (adrenocorticotropic hormone) and was originally developed and used in Russia for ischemic stroke and cognitive impairment, with nootropic (cognition-focused) effects being its main claim ^[7]. Selank is derived from tuftsin and is framed primarily as an anxiolytic. In practice, people researching either one for focus or mood often conflate the two because they're sold by the same suppliers, dosed similarly (intranasal drops or spray), and share the same evidentiary problem: promising Russian data, no Western replication. If your main goal is anxiety relief, selank's literature is the more directly relevant one. If your goal is primarily cognitive sharpness or post-stroke recovery, semax's literature is what people usually cite, though it carries the identical caveat about limited independent verification outside Russia. Don't assume findings about one transfer to the other. They're different molecules with different receptor-adjacent mechanisms proposed in the literature, even though the marketing often treats them as a matched pair.

What does the research quality actually look like?

This is the part worth being blunt about. Most selank studies are published in Russian-language journals (Zhurnal Nevrologii i Psikhiatrii, Farmakologiya i Toksikologiya-adjacent outlets), often with sample sizes in the dozens to low hundreds, and not consistently reproduced by independent labs outside Russia ^[2][3]. Some are available only as abstracts in English-language databases like PubMed, with the full methodology behind a Russian-language paywall or not translated at all. That doesn't make the research worthless. Russian psychopharmacology has a real, decades-long tradition, and Zakusov Institute researchers were serious pharmacologists working through standard animal-model and small-human-trial pipelines. But 'published in a Russian journal' is not equivalent to 'validated by the peer review standards and replication expectations that govern something like a JAMA Psychiatry or Lancet Psychiatry trial.' No selank trial has appeared in a top-tier Western psychiatric journal as of this writing, and no phase 3-scale randomized controlled trial (the standard the FDA requires for antidepressant approval) has been conducted anywhere. Here's a rough comparison of what exists for selank versus a standard SSRI at the point of FDA approval: | Evidence factor | Selank (GAD/anxiety studies) | Typical approved SSRI (e.g., sertraline) |

What are the known side effects of selank, especially alongside other medications?

Reported side effects in the Russian clinical literature are generally mild: some studies note transient nasal irritation with intranasal dosing, mild drowsiness, or headache in a minority of subjects, with no serious adverse events reported in the trials that exist ^[3]. Selank has not been associated with the withdrawal or discontinuation syndromes seen with benzodiazepines or some antidepressants. The honest gap is drug-drug interaction data. Nobody has systematically studied selank in patients taking SSRIs, SNRIs, MAOIs, tricyclics, mood stabilizers, or antipsychotics at the scale needed to rule out interactions. If you're on an antidepressant already, especially anything with serotonergic activity, adding an unregulated peptide without your prescriber knowing removes their ability to spot an adverse pattern early. That's true even if the underlying risk turns out to be low. People with a history of serotonin syndrome, those on MAOIs (where interaction risk with almost anything serotonergic climbs sharply), and anyone titrating a new antidepressant dose are the groups where caution matters most. This isn't a theoretical warning; MAOI combinations are already flagged by the FDA as high risk with numerous serotonergic substances ^[4], and selank's serotonin-adjacent mechanism means it hasn't been cleared from that concern, only untested against it.

Should you talk to a doctor before combining selank with an antidepressant?

Yes, and this is the section to actually act on. Selank is not FDA approved, is not a controlled substance in the US, and is typically obtained through compounding pharmacies via a prescriber, not over the counter ^[5]. That structure exists precisely because peptides like this benefit from clinical oversight, not because of a formal safety mandate specific to selank. If you're currently taking an antidepressant and considering selank for anxiety on top of it, the conversation with your prescriber should cover three things: what you're taking now and at what dose, why you think selank might help beyond what your current medication is doing, and whether your prescriber has any concern about serotonergic load or interaction given your specific drug and dose. A psychiatrist or primary care doctor won't have Russian clinical trial data memorized, but they can assess your actual medication list for real interaction risk, which matters more than any peptide study. Selank Co works with a provider-reviewed process that connects people to a licensed prescriber and a compounding pharmacy partner for fulfillment, rather than selling directly. That's a meaningfully different model than a research-chemical vendor shipping a vial with no clinical touchpoint at all, and it's the route worth taking if you're going to try this alongside existing medication.

How does selank compare to other options for anxiety on top of an antidepressant?

If your antidepressant isn't fully controlling anxiety symptoms, the standard, evidence-backed next steps are usually dose adjustment, adding a second agent your prescriber has real trial data on (like buspirone, or short-term benzodiazepine use), or adding cognitive behavioral therapy, which has strong randomized trial support for anxiety disorders ^[9]. Selank sits well outside that established toolkit. Where selank might make sense to someone is as a low-risk-seeming experiment after those standard options have been discussed, not instead of them. It has a relatively benign short-term side effect profile in the trials that exist, no known abuse potential, and no documented withdrawal syndrome ^[3]. But 'relatively benign in a handful of Russian trials' is a much lower bar than 'proven safe and effective in your specific clinical situation, on your specific antidepressant.' For a broader before/after picture of what people report, selank before and after covers real-world reported timelines, and selank success rate covers how often people report meaningful benefit versus none at all, to the extent that can be estimated from available reporting rather than a formal trial registry.

Frequently asked questions

Can I take selank with my SSRI?

There's no published clinical trial testing selank combined with SSRIs like sertraline or fluoxetine. Mechanistically, selank is metabolized differently (peptidase breakdown, not liver CYP enzymes), which suggests lower interaction risk, but that's inference, not data. Talk to your prescriber before combining, since nobody is tracking real-world interaction reports for this specific pairing.

Is selank an antidepressant?

Not in the FDA or clinical sense. Selank is studied and marketed mainly as an anxiolytic with some nootropic effects. Some Russian research shows antidepressant-like activity in animal models compared to amitriptyline, but no trial positions it as a standalone depression treatment, and it isn't approved for that use anywhere.

Is selank FDA approved?

No. Selank has no FDA approval for any indication in the United States. It has regulatory approval for medical use in Russia, which followed a different review process than the FDA's New Drug Application pathway and does not carry the same evidentiary weight or oversight.

What's the difference between selank and semax?

Both are Russian-developed peptides from the same research institutes, but selank comes from tuftsin and is studied mainly for anxiety, while semax comes from ACTH and is studied mainly for cognition and post-stroke recovery. They're often sold together but have different proposed mechanisms and different evidence bases.

Can selank cause serotonin syndrome with antidepressants?

No case reports of serotonin syndrome from selank exist in the published literature, but that likely reflects how few people have combined it with prescription antidepressants under medical observation, not proof of safety. Anyone on an MAOI or high-dose serotonergic medication should treat this as an unstudied combination.

Does selank have withdrawal effects like some antidepressants do?

Russian trials report no withdrawal or discontinuation syndrome associated with stopping selank, unlike some SSRIs and SNRIs which can cause discontinuation symptoms (dizziness, brain zaps, irritability) if stopped abruptly. Sample sizes in these trials are small, though, so long-term discontinuation data is thin.

Is the Russian research on selank trustworthy?

It's real pharmacology from an established research tradition (the Zakusov Institute and Institute of Molecular Genetics), but it hasn't been replicated by independent Western labs, sample sizes are often modest, and no trial has appeared in a top-tier international psychiatric journal. Treat it as promising but unconfirmed, not disproven.

Should I stop my antidepressant to try selank instead?

No. Selank has nowhere near the trial depth or regulatory scrutiny that approved antidepressants have. Stopping a prescribed antidepressant risks relapse of your underlying condition and possible discontinuation symptoms. If you want to explore selank, do it alongside your prescriber's involvement, not as a replacement.

What side effects does selank have on its own?

Reported side effects in Russian trials are mild: transient nasal irritation with intranasal dosing, occasional mild drowsiness or headache. No serious adverse events have been reported in the published studies, though trial durations are typically short (two to four weeks).

Where can I get selank legally in the US?

Selank is not FDA approved and isn't sold over the counter as a drug. It's typically obtained through a licensed prescriber working with a compounding pharmacy. Selank Co's provider-reviewed process connects people to that pathway rather than shipping product directly.

Does selank interact with benzodiazepines?

No published trial specifically tests selank combined with benzodiazepines like alprazolam or clonazepam. Selank is sometimes framed as a non-sedating alternative to benzodiazepines for anxiety, but that framing comes from separate studies, not from a combination trial, so interaction risk is unknown.

How is selank studied differently from a typical antidepressant trial?

Selank trials tend to run two to four weeks with sample sizes from dozens to a few hundred participants, published mainly in Russian journals. Typical antidepressant approval trials (per FDA review) involve thousands of patients across multiple phases with years of post-marketing surveillance, a much larger and longer evidence base.

Sources

1. Zakusov Institute of Pharmacology, peptide anxiolytic research overview: Selank was developed as an anxiolytic peptide derived from tuftsin, studied for reduced sedation risk compared to benzodiazepines
2. Pharmacology, Biochemistry and Behavior, selank and BDNF/monoamine study: Selank shows antidepressant-like activity in animal models linked to BDNF and monoamine changes, compared against amitriptyline
3. PubMed, selank clinical trial in generalized anxiety and adjustment disorders: Selank reduced anxiety symptoms in short clinical trials without reported withdrawal effects
4. FDA, drug safety communication on serotonin syndrome risk: Combining multiple serotonergic drugs carries a documented risk of serotonin syndrome
5. FDA, compounding and unapproved drug substances guidance: Selank has no FDA approval and is only available in the US through compounding pathways
6. FDA, antidepressant discontinuation and labeling information: Abruptly stopping an antidepressant can cause discontinuation symptoms and relapse risk
7. PubMed, semax pharmacology and stroke research overview: Semax is derived from ACTH and studied mainly for cognitive and post-stroke recovery effects, distinct from selank's anxiolytic focus
8. FDA, sertraline (Zoloft) approval and clinical trial summary: Approved SSRIs like sertraline were reviewed through multi-phase trials involving thousands of patients before FDA approval
9. National Institute of Mental Health, psychotherapy for anxiety disorders: Cognitive behavioral therapy has established randomized trial support as a treatment for anxiety disorders